UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.82-90

2015

Volltextzugriff (PDF)

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Thrombosis and haemostasis, 2017-02, Vol.117 (2), p.238

2017

Volltextzugriff (PDF)

Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation

European journal of heart failure, 2023-06, Vol.25 (6), p.832-841

2023

Volltextzugriff (PDF)

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Circulation (New York, N.Y.), 2019-02, Vol.139 (6), p.760-771

2019

Volltextzugriff (PDF)

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

European heart journal, 2019-05, Vol.40 (19), p.1541-1550

2019

Volltextzugriff (PDF)

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial

European heart journal, 2021-05, Vol.42 (17), p.1698-1706

2021

Volltextzugriff (PDF)

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease

Journal of the American College of Cardiology, 2019-07, Vol.74 (2), p.179-189

2019

Volltextzugriff (PDF)

Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2019-11, Vol.140 (22), p.1792-1801

2019

Volltextzugriff (PDF)

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial

International journal of cardiology, 2020-04, Vol.304, p.185-191

2020

Volltextzugriff (PDF)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Circulation (New York, N.Y.), 2021-02, Vol.143 (7), p.673-684

2021

Volltextzugriff (PDF)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

Critical care (London, England), 2016-09, Vol.20 (1), p.273-273, Article 273

2016

Volltextzugriff (PDF)

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial

Journal of clinical neuroscience, 2021-04, Vol.86, p.294-300

2021

Volltextzugriff (PDF)

Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48

European heart journal. Cardiovascular pharmacotherapy, 2022-11, Vol.8 (7), p.695-706

2022

Volltextzugriff (PDF)

Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study

Vascular medicine (London, England), 2016-08, Vol.21 (4), p.361-368

2016

Volltextzugriff (PDF)

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Blood, 2013-11, Vol.122 (21), p.211-211

2013

Volltextzugriff (PDF)

Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48

European heart journal. Cardiovascular pharmacotherapy, 2021-12

2021

Volltextzugriff (PDF)

Abstract 14367: Biomarkers for the Assessment of Stroke/Systemic Embolism and Bleeding Risk in Patients With Atrial Fibrillation: A Nested Observational Study From ENGAGE AF-TIMI 48

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A14367-A14367

2018

Volltextzugriff (PDF)

In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

Angiogenesis (London), 2022-11, Vol.25 (4), p.455-470

2022

Volltextzugriff (PDF)

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

The New England journal of medicine, 2021-12, Vol.385 (23), p.2150-2160

2021

Volltextzugriff (PDF)

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

The New England journal of medicine, 2013-10, Vol.369 (15), p.1406-1415

2013

Volltextzugriff (PDF)

Radiation Metabolomics. 4. UPLC-ESI-QTOFMS-Based Metabolomics for Urinary Biomarker Discovery in Gamma-Irradiated Rats

Radiation research, 2011-04, Vol.175 (4), p.473-484

2011

Volltextzugriff (PDF)

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)

Circulation. Arrhythmia and electrophysiology, 2017-01, Vol.10 (1), p.e004267-e004267

2017

Volltextzugriff (PDF)

Comparison of electrodiagnosis, neurosonography and MR neurography in localization of ulnar neuropathy at the elbow

Journal of neuroradiology, 2022-01, Vol.49 (1), p.9-16

2022

Volltextzugriff (PDF)

Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study

The American heart journal, 2021-05, Vol.235, p.132-139

2021

Volltextzugriff (PDF)

Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response: A Controlled Trial

Journal of clinical psychopharmacology, 2013-04, Vol.33 (2), p.193-198

2013

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Humans
(17)
Cardiovascular System & Cardiology
(15)
Atrial Fibrillation
(14)
Cardiac & Cardiovascular Systems
(12)
Male
(12)
Female
(11)
Anticoagulants
(10)
Stroke
(9)
Aged
(8)
Middle Aged
(7)
Peripheral Vascular Disease
(7)
Edoxaban
(6)
Factor Xa Inhibitors - Therapeutic Use
(6)
Pyridines - Therapeutic Use
(6)
Thiazoles - Therapeutic Use
(6)
Anticoagulants - Therapeutic Use
(5)
Atrial Fibrillation - Drug Therapy
(5)
Double-Blind Method
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease

Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial

Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48

Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48

Abstract 14367: Biomarkers for the Assessment of Stroke/Systemic Embolism and Bleeding Risk in Patients With Atrial Fibrillation: A Nested Observational Study From ENGAGE AF-TIMI 48

In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

Radiation Metabolomics. 4. UPLC-ESI-QTOFMS-Based Metabolomics for Urinary Biomarker Discovery in Gamma-Irradiated Rats

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)

Comparison of electrodiagnosis, neurosonography and MR neurography in localization of ulnar neuropathy at the elbow

Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study

Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response: A Controlled Trial

Suchergebnisse filtern